Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

A.P. Pharma: Refiling of NDA for APF530 Could Lead to Stock Price Strength

Catalyst
AP Pharma (APPA.OB) announced that it has resubmitted its New Drug Application (NDA) to the FDA for its lead product…
Read more…

Recently Added Board Member Brings Great Expertise to the Potential Launch of APF530 (APPA, $0.64)

Investment Thesis and Price Target
I initiated coverage of A.P. Pharma (APPA.OB) with a buy at $0.42 per share on April…
Read more…

A.P. Pharma: Ondansetronís Link to QT Interval Prolongation is a Huge Positive for APF530 (APPA, $0.68)

Investment Thesis
The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran)…
Read more…

Initiating Coverage of A.P. Pharma with a Buy (APPA, $0.42)

I have just published a report initiating coverage on A.P. Pharma (APPA, $0.42) in which I recommend purchase; my 2015…
Read more…